The aim of work was to formulate and evaluate cubic formulation of Pyrazinamideto improve the bioavailability of the drug. Different formulations of Pyrazinamide cubosomes were prepared by Top down approach using GMO as lipid phase vehicle, Poloxamer 407 as stabilizer and distilled water as aqueous phase by varying the concentrations of GMO and Poloxamer 407. The effect of stabilizer concentration was investigated to determine their effects on the morphological and dimensional characteristics of cubosomes. At the optimized homogenization conditions, cubosomes with reproducible, narrow particle size distribution and a mean particle size of 180 nm±4.9 nm were obtained. Resultant formulations were characterized for particle size, surface morphology, encapsulation efficiency, in-vitro dissolution and diffusion studies. Structure characterization was confirmed that loading of Pyrazinamide shows no disturbance in the structure of formed cubosomes. The encapsulation efficiency determined by UV spectroscopy and further confirmed that Pyrazinamide was successfully encapsulated in Cubosomes.
